EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Efficacy and immune-related adverse events of pembrolizumab with bone-modifying agents in female patients with breast cancer

Alexis LeVee iD, Esther Peluso, Melissa G Lechner iD, Nora Ruel iD, Joanne Mortimer iD, Irene Kang iD, Karen Tsai iD

The Oncologist · 2025

DOI: 10.1093/oncolo/oyaf134 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Oncologist, 2025. Verfasst von Alexis LeVee und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA, United States. Hauptthemen laut MEDLINE: Breast Neoplasms, Antibodies, Monoclonal, Humanized, Bone Density Conservation Agents, Antineoplastic Agents, Immunological. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIDDK NIH HHS, NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Emerging studies demonstrate that some bone-modifying agents (BMAs), such as denosumab (Dmab), can modulate immune responses by increasing tumor-infiltrating T cells and expanding the T-cell repertoire. Female patients with breast cancer in particular often receive concurrent treatment with immune checkpoint inhibitors (ICI) and BMAs. However, the clinical impact of BMAs on immune-related adverse events (irAE) and cancer outcomes in patients treated with ICI remains poorly understood. Materials and methods Female patients with breast cancer treated with pembrolizumab between 2017 and 2024 were included. Patients were categorized according to BMA received: zoledronic acid (ZA), Dmab, or none. BMA therapy was considered received within a dose interval prior to ICI (12 months for ZA; 6 months for Dmab), during ICI therapy, or within 1 month of the last ICI dose.

Results

In a cohort of 425 female patients with breast cancer treated with pembrolizumab, 55 (12.9%) received Dmab, 31 (7.3%) received ZA, and 339 (80.0%) received no BMA. A total of 255 (60%) patients had early-stage breast cancer, and 170 (40%) had metastatic disease. After a median follow-up of 19.4 months (95% CI, 17.5-20.8), the incidence of severe irAE was higher in patients who received Dmab vs those who received no BMA (21.8% vs 11.5%, P = .04). Patients who received Dmab had higher responses (48.0%) compared to those who received ZA (31.6%) and no BMA (35.0%), although not statistically significant (P = .3).

Conclusion

This is the first study to suggest an increased rate of severe irAE and potential synergistic anti-tumor effect of Dmab in combination with ICI in female patients with breast cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsAntibodies, Monoclonal, HumanizedBone Density Conservation AgentsAntineoplastic Agents, ImmunologicalHumansFemaleMiddle AgedAgedDenosumabZoledronic AcidAdultImmune Checkpoint InhibitorsAged, 80 and over

Stichwörter der Autor:innen

breast cancerdenosumabimmune-related adverse eventsimmunotherapypembrolizumab

Substanzen

pembrolizumabAntibodies, Monoclonal, HumanizedBone Density Conservation AgentsDenosumabZoledronic AcidImmune Checkpoint InhibitorsAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA, United States.
  • UCLA/Caltech Medical Scientist Training Program, Los Angeles, CA, United States.
  • Division of Endocrinology, UCLA Geffen School of Medicine, Los Angeles, California, United States.
  • Department of Biostatistics, City of Hope Comprehensive Cancer Center, Duarte, CA, United States.
  • Department of Diabetes, Endocrinology and Metabolism, City of Hope Comprehensive Cancer Center, Duarte, CA, United States.

ORCID-Profile: Alexis LeVee, Melissa G Lechner, Nora Ruel, Joanne Mortimer, Irene Kang, Karen Tsai

Förderung

  • NIDDK NIH HHS
  • NIAID NIH HHS

Zitieren

APA

LeVee, A., Peluso, E., Lechner, M. G., Ruel, N., Mortimer, J., Kang, I., & Tsai, K. (2025). Efficacy and immune-related adverse events of pembrolizumab with bone-modifying agents in female patients with breast cancer. The Oncologist. https://doi.org/10.1093/oncolo/oyaf134

Vancouver

LeVee A, Peluso E, Lechner MG, Ruel N, Mortimer J, Kang I, et al. Efficacy and immune-related adverse events of pembrolizumab with bone-modifying agents in female patients with breast cancer. The Oncologist. 2025. doi:10.1093/oncolo/oyaf134

BibTeX
@article{LeVee2025,
  author = {LeVee, Alexis and Peluso, Esther and Lechner, Melissa G and Ruel, Nora and Mortimer, Joanne and Kang, Irene and Tsai, Karen},
  title = {Efficacy and immune-related adverse events of pembrolizumab with bone-modifying agents in female patients with breast cancer},
  journal = {The Oncologist},
  year = {2025},
  doi = {10.1093/oncolo/oyaf134}
}
Kostenlos starten →